Ted Tisch, Janice Chen, Lucas Harrington, Trevor Martin and Peter Nell. (Mammoth)

January 30, 2020 12:21 PM ESTUpdated January 30, 08:48 PM

Doudna-founded CRISPR upstart bags $45M for new Cas research, extends its reach into therapeutics

Amber Tong

Senior Editor

The South San Francisco-based CRISPR upstart that set out to develop diagnostics under co-founder Jennifer Doudna’s guidance is back with $45 million in funding — and new ambitions in therapeutics.

Mammoth Biosciences is also putting its tech to the test amid heightened vigilance surrounding the novel coronavirus emerging out of Wuhan, China. The goal is to prototype a rapid molecular test that can be used at point of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Doudna-founded CRISPR upstart bags $45M for new Cas research, extends its reach into therapeutics

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Doud­na-found­ed CRISPR up­start bags $45M for new Cas re­search, ex­tends its reach in­to ther­a­peu­tics

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

Doudna-founded CRISPR upstart bags $45M for new Cas research, extends its reach into therapeutics

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa